Wilms tumor 1 (WT1) is considered to be a promising target of cancer treatment because it has been reported to be frequently expressed at high levels in various malignancies. Although WT1-targeted cancer treatment has been initiated, conclusive detection methods for WT1 are not established. The present study aimed to consolidate immunohistochemistry for WT1 with statistical basis. Transfected cells with forced WT1 expression yielded specific western blot bands and nuclear immunostaining; cytoplasmic immunostaining was not specifically recognized. Immunohistochemistry, western blotting, and quantitative reverse transcriptase-polymerase chain reaction were performed in 35 human cell lines using multiple WT1 antibodies and their results were quantified. Relationships among the quantified results were statistically analyzed; the nuclear immunostaining positively correlated with western blot bands and mRNA expression levels, whereas cytoplasmic immunostaining did not. These results indicate that nuclear immunostaining reflects WT1 expression but cytoplasmic immunostaining does not. The nuclear immunostaining was barely (3/541) observed in primary cancer of esophagus, bile duct, pancreas and lung. Although the present study has some limitations, the results indicate that the cytoplasmic immunostaining does not correlate with actual WT1 expression and prompts researchers to carefully evaluate target molecule expression in treatment of cancer.
Introduction
The Wilms tumor 1 (WT1) gene was initially identified in 1990 as a tumor-suppressor gene of Wilms tumor (1, 2) . WT1, which contains four C-terminal zinc-finger motifs and an N-terminal DNA-binding domain, functions as a transcription factor in regulation of differentiation and development of mesodermally derived tissues such as kidney, mesothelium and gonad (3) (4) (5) . WT1 has been reported to be strongly expressed in benign mesodermal tissues, as well as in malignancies of mesodermal origin such as leukemia (44-93%) (6, 7) , mesothelioma (72-100%) (8) (9) (10) (11) (12) (13) (14) and ovarian serous carcinomas (45-100%) (11, 13, 15, 16) . Therefore, WT1 mRNA is used as a clinical standard marker to diagnose minimal residual disease of leukemia (6) and immunohistochemical study for WT1 is helpful to distinguish mesodermally derived solid cancers such as mesothelioma and ovarian cancer from other solid cancers (8, (10) (11) (12) (13) 15, 16) .
On the other hand, WT1 attracts many researchers as an ideal target for cancer treatment. WT1 was prioritized as a promising target of immunotherapy against various malignancies (17) because dozens of studies have confirmed WT1 overexpression not only in mesodermally derived malignancies but also in a variety of non-mesodermal origin solid cancers such as esophageal (45-95%) (18, 19) , gastric (42%) (19) , colon (69-89%) (19, 20) , hepatocellular (95%) (21) , bile duct (68%) (19) , pancreatic (65-75%) (19, 22) , thyroid (95%) (23), prostate (25%) (9) , lung (30-83%) (19, 24) , breast (26-87%) (19, (25) (26) (27) , Tissue samples. Cancer tissues and corresponding normal epithelial tissues were obtained from 552 patients with esophageal (101 patients), bile duct (96 patients), pancreatic (99 patients), and lung cancer (256 patients) who underwent resection in the Department of Gastroenterological surgery II, hokkaido University, Japan between 1994 and 2005. These tissue samples were fixed in 10% formalin and embedded in paraffin blocks. Three or four spots of each tissue, of uniform 0.6-mm diameter, were punched out and consolidated into 25 paraffin blocks using a Manual Tissue Arrayer (Beecher Instruments, Inc., sun Prairie, WI, UsA); the resultant 25 blocks were used for immunohistochemistry. As possible positive controls for WT1 expression in tissue samples, kidney, pleura, testis, pleural mesothelioma and ovarian serous adenocarcinoma were also examined under the same conditions. Gene cloning and transfection. Negative and positive controls for WT1 protein expression were generated as follows. First, internal ribosome entry site and complementary DNA (cDNA) encoding green fluorescent protein (GFP) were cloned into the multiple cloning site of plasmid vector pcDNA3.1(+) (Invitrogen); the resultant plasmid is termed empty vector. WT1 cDNA was amplified by polymerase chain reaction (PCR), using human kidney QUICk-Clone cDNA (Takara, Otsu, Japan) as a template and cloned into empty vector. The resultant plasmid vector is termed vector WT1. The base sequence of vector WT1 was confirmed by the singlenucleotide primer extension method. Empty vector and vector WT1 were transfected into 293FT and heLa cells using Lipofectamine 2000 (Invitrogen). successful transfection was verified by observing GFP expression. Cells transfected with empty vector and vector WT1 were, respectively, used as negative and positive controls for WT1 protein expression. The WT1 mRNA contains two splice sites that can be skipped during RNA splicing; consequently, the WT1 gene encodes four variant isoforms of WT1 protein ( Fig. 1 ). We constructed the corresponding four types of positive controls for WT1 protein expression.
Transfected cells producing fusion protein GFP-WT1 were generated as follows. GFP cDNA was cloned into the multiple cloning site of pcDNA3.1(+); the resultant plasmid is termed vector GFP. WT1 cDNA was cloned into vector GFP such that the WT1 cDNA sequence was fused to the C-terminus of the GFP cDNA, which lacked a stop codon; the resultant plasmid is termed vector GFP-WT1. The base sequence of vector GFP-WT1 was confirmed by the single-nucleotide primer extension method. Vector GFP and vector GFP-WT1 were transfected into 293FT and heLa cells using Lipofectamine LTX (Invitrogen). Cells transfected with vector GFP and vector GFP-WT1 were predicted to produce GFP and fusion protein GFP-WT1, respectively. As noted above, the WT1 mRNA has four splicing variants ( Fig. 1) ; therefore, we constructed the corresponding four types of vector GFP-WT1 plasmids.
Immunohistochemistry. Cultured cells which were detached using 0.25% trypsin and sedimented by centrifugation or excised tissue samples were fixed in 10% formalin and embedded in paraffin blocks. Thin sections (2 µm thick) were de-waxed and rehydrated, and antigens were retrieved in pressure vessels under the following conditions: citrate buffer (pH 7.0), 2 atm, 100˚C, 2 min. For additional antigen retrieval, sections for WT1 antibody 6F-h2 were incubated for 5 min at room temperature with 10% proteinase k ready-to-use enzyme (Dako, Kyoto, Japan) before treatment in the pressure vessels. The sections were immersed for 15 min at room temperature in 0.3% h 2 O 2 diluted with methanol, in order to block endogenous peroxidase activity, and then incubated in 10% normal goat serum (Nichirei Corp., Tokyo, Japan) at room temperature for 30 min to reduce non-specific binding. WT1 antibodies 6F-h2 (mouse monoclonal; Dako), ab89901 (rabbit monoclonal; Abcam, Cambridge, Uk) and C-19 (rabbit polyclonal; Santa Cruz Biotechnology, Dallas, TX, USA), used as primary antibodies ( Fig. 1 ), were diluted 1:100, 1:200 and 1:100, respectively, with antibody diluent (Dako). The sections were incubated with the diluted primary antibodies at 4˚C overnight. Mouse IgG1 (Dako) and rabbit polyclonal IgG (Abcam) were used for negative controls against samples with primary antibodies. Next, sections were incubated for 30 min at room temperature with biotinylated goat antibody to mouse and rabbit immunoglobulin (Histofine Simple Stain MAX PO MULTI; Nichirei Corp.). Finally, sections were stained with 3-3'-diaminobenzidine tetrahydrochloride (Histofine Simple stain DAb solution; Nichirei Corp.) and then lightly counterstained by hematoxylin.
In cell lines, immunostaining scores for the entire nucleus, the nuclear bodies, and the cytoplasm were calculated independently. Immunostaining intensities of entire nucleus and cytoplasm in individual cells were classified into four grades and intensity of nuclear bodies was classified into two grades as shown in Fig. 2 . Immunostaining scores for samples were calculated as the sum of the immunostaining intensities of individual cells, divided by the total number of the cells; thus, the score represents the average immunostaining intensity of all cells in the sample. Immunostaining scores were independently calculated by two surgeons under the guidance of a pathologist and the average value was regarded as the final immunostaining score.
Western blotting. Total protein was extracted from cultured cells using triple-detergent lysis buffer. Protein concentration was measured by the bradford method using a commercial protein assay kit (bio-Rad Laboratories, hercules, CA, UsA). Protein was boiled for 2 min for antigen retrieval, subjected to sDs-PAGE, and blotted onto a hybond-ECL nitrocellulose membrane (GE healthcare Life sciences, Piscataway, NJ, USA). The membrane was blocked at 4˚C overnight with 5% skim milk, incubated with diluted primary antibodies at room temperature for 1 h, and then incubated with diluted secondary antibodies at room temperature for 1 h. WT1 antibodies 6F-h2, ab89901 and C-19 ( Fig. 1 ), mouse monoclonal GFP antibody (Clontech Laboratories, Inc., Otsu, Japan) and actin C4 antibody (Millipore, billerica, MA, UsA) were used as primary antibodies. Peroxidase-conjugated AffiniPure Goat Anti-Mouse IgG h+L antibodies (Jackson ImmunoResearch, West Grove, PA, USA) or peroxidase-conjugated AffiniPure Goat Anti-Rabbit IgG h+L antibodies (Jackson ImmunoResearch) were used as secondary antibodies. Protein bands were visualized using the ECL-Plus Western blotting detection system (GE healthcare Life sciences) and Detector Lumino Imaging Analyzer model FAS-1000 (Toyobo, Co., Ltd., Osaka, Japan). Intensities of protein bands were quantitated using ImageJ (http://rsbweb.nih.gov/ij/), corrected for the intensities of the corresponding actin bands, and normalized to the intensity Table I . Two patterns of experimental conditions used in western blotting.
Amount
Dilution factor of protein (Table I) , were used. however, the intensities of protein bands were compared under the same conditions.
Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR). Total RNA was extracted from cultured cells using the TRI reagent (sigma-Aldrich). Possible DNA contamination was eliminated using RQ1 RNase-Free DNase (Promega, Tokyo, Japan). After the DNase treatment, the absence of DNA contamination was confirmed by PCR using the primers for β-actin (described below). cDNA was synthesized from mRNA by reverse transcription reaction using the superscript VILO cDNA synthesis kit (Invitrogen). cDNA diluted 20-fold with double-distilled water was used as a template for quantitative PCR. Quantitative PCR was performed by two methods: the intercalator-based method using Power sYbR-Green PCR Master Mix (Applied Biosystems, Tokyo, Japan) and the fluorescent probe-based method using TaqMan Universal Master Mix II (Applied biosystems). Reaction conditions consisted of 40 cycles of 94˚C for 30 sec, 60.4˚C for 30 sec and 72˚C for 30 sec. All reactions were performed in triplicate. The results of quantitative PCR were analyzed on an ABI PRISM 7000 sequence detection system (Applied biosystems). Expression levels of WT1 mRNA were normalized to the corresponding β-actin mRNA and relativized considering those of WT1 mRNA of k562 as 1.
The base sequences of primers and internal probes were as follows: WT1 sense primer, 5'-TGCGGAGCCCAATACA GAATACAC-3' and WT1 reverse primer, 5'-TCAGATGCCG ACCGTACAAGAG-3'; WT1 internal probe, 5'-FAM-AGA GGCATTCAGGATGTGCGACG-TAMRA-3'; β-actin sense primer, 5'-CAACCGCGAGAAGATGACCC-3' and β-actin reverse primer, 5'-ACCGGAGTCCATCACGATGC-3'; β-actin internal probe, 5'-FAM-CCAGGCTGTGCTATCCCTGTA CGC-TAMRA-3'. The primers for WT1 were designed to bind to WT1 cDNA between exons 6 and 7, so that the four spliced variants of WT1 cDNA were all recognized ( Fig. 1 ). The primers for β-actin were designed to bind to β-actin cDNA between exons 3 and 4.
Statistical analysis. Correlation of paired quantitative variables was evaluated by the spearman rank method using statView version 5.0 software (sAs Institute, Inc., Cary, NC, USA). Differences were considered significant when r >0.4 and P<0.05.
Results

WT1 expression in transfected cells. We transfected 293FT
and heLa with vectors encoding the four splice variants of WT1 ( Fig. 1 ). WT1-transfected cells were expected to produce excessive exogenous WT1 protein. As shown in Fig. 3 , western blotting with two WT1-specific monoclonal antibodies (6F-H2 and ab89901) and one WT1-reactive polyclonal antibody (C-19) yielded clear 50-55-kDa bands in cells expressing any of the four WT1 variants, even though the antibodies recognize different sites ( Fig. 1 ). Immunohistochemistry with these three antibodies resulted in strong staining in the nucleus of all WT1 transfectants, corresponding to the appearance of the 50-55-kDa bands in western blotting. In addition to the nuclear staining, these antibodies yielded modest cytoplasmic staining in various cells including empty-vector transfectants. Especially, C-19 yielded significant cytoplasmic immunostaining in all tested cells, regardless of their transfection status. In conclusion, enforced WT1 expression was detected in the nucleus of the two different cell lines by the three different antibodies. Polyclonal C-19 antibody may exhibit non-specific as well as specific reactivity. We used these transfectants as positive and negative controls for further analyses. . Western blotting for transfected 293FT and heLa cells was done under Condition A and b, respectively (as described in Table I ).
Comparison of the results of WT1-immunohistochemistry with those of other detection methods using cell lines. by itself, immunohistochemistry does not distinguish specific from non-specific staining, because it does not provide the information such as the molecular weights or sequences of the detected proteins. To verify the specificity for endogenous WT1 in immunohistochemistry, we compared results of WT1-immunohistochemistry with those of western blotting and qRT-PCR in 35 human cell lines. Fig. 4 shows the results of immunohistochemistry, western blotting and qRT-PCR. For immunohistochemistry, immunostaining scores were calculated independently in the entire nucleus, the nuclear bodies and the cytoplasm (Fig. 2) . In western blotting, multiple protein bands with different molecular weights were observed; these bands were classified into A-G ( Fig. 4B) and their intensities were, respectively, quantified. In qRT-PCR, we used both intercalator-based and fluorescent probe-based methods. Table II shows all quantified results: the immunostaining scores, the intensities of western blotting bands and WT1 mRNA levels. Table III shows the relationships among quantified results from immunohistochemistry, western blotting and qRT-PCR of the 35 cell lines; positive correlations in significance (both r>0.4 and P<0.05) are indicated in bold. Any relationship among the intensities of western blot bands and WT1 mRNA expression levels yielded strongly positive correlations with statistical significance, with the exception of relationships including western blot band b. The immunostaining scores of the entire nucleus generated by monoclonal 6F-h2 positively correlated with any intensity of western blotting bands other than band b, as well as any WT1 mRNA expression levels. The immunostaining scores of the entire nucleus by monoclonal Table I ). 'Non-treated' indicates protein extracted from host cells not subjected to any treatment. 'No vector' indicates protein extracted from host cells subjected to mock transfection (i.e., transfection reagent but no plasmids). 'Vector WT1' indicates the 1 µg of protein from vector WT1 transfectants mixed with 19 µg of protein from empty vector transfectants. Western blot bands of 60, 57 and 50-55 kDa detected by 6F-h2 were named A, b and C, respectively; bands of 60 and 50-55 kDa detected by ab89901, D and E; bands of 60 and 50-55 kDa detected by C-19, F and G. sCC, squamous cell carcinoma. (C) Results of qRT-PCR for 35 cell lines. WT1 mRNA expression was normalized to the corresponding β-actin mRNA level and further normalized to the level of WT1 mRNA in K562 (defined as 1). Gray and white bars represent the average values of the relative quantities of WT1 mRNA detected by the intercalator-based method and the fluorescent probe-based method, respectively. Error bars represent standard deviation. 
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Intensities of western blotting bands Table III . Continued.
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Immunostaining scores
Intensities of western blot bands ab89901 positively correlated with the nuclear immunostaining scores by 6F-h2, intensities of multiple western blot bands, and WT1 mRNA expression levels. by contrast, the immunostaining scores of the entire nucleus by polyclonal C-19 did not correlate with intensities of western blot bands or WT1 mRNA expression levels. No significant correlations were observed between any immunostaining score of the nuclear bodies or cytoplasm generated by three WT1 antibodies and any result of western blotting or qRT-PCR. These results suggest that western blot bands except for band b and WT1 mRNA expression levels are credible indicators of endogenous WT1 expression. In attunement with them, nuclear immunostaining using 6F-h2 and ab89901 seems to quantitatively reflect endogenous WT1 expression. by contrast, cytoplasmic immunostaining using WT1 antibodies does not specifically reflect WT1 expression because it did not have any significant association with results from other detection methods.
Intracellular localization of GFP-WT1 fusion protein.
To verify the intracellular localization of WT1 protein by another method, we examined the localization of GFP-WT1 fusion protein. Fig. 5 shows microscopic images of cells transfected with vector GFP-WT1. While green fluorescence was observed in both the nucleus and the cytoplasm of cells transduced with GFP alone, it was observed only in the nucleus of cells transfected with vector GFP-WT1. Expression of GFP-WT1 fusion protein in the transfectants was confirmed by western blotting (Fig. 6) . These results indicate that WT1 protein strongly prefers to be concentrated in the nucleus supporting the idea that nuclear immunostaining quantitatively reflects WT1 expression.
WT1 expression in human tissue samples. We examined WT1 expression in primary cancer tissue samples of esophagus, bile duct, pancreas and lung with the corresponding normal epithelial tissues by immunohistochemistry using 6F-h2, an antibody shown above to be appropriate for WT1-immunohistochemistry. As shown in Fig. 7 and Table IV , nuclear immunostaining was almost never detected in cancer cells or normal epithelium of esophagus, bile duct, pancreas, and lung, whereas it was firmly observed in mesothelioma, ovarian cancer and healthy tissues such as kidney and pleura.
Discussion
In the present study, we attempted to validate WT1-immunohistochemistry for solid tumors quantifying WT1 gene products. Utilizing multiple different detection methods and WT1 antibodies, along with defined positive and negative controls, we revealed that only nuclear staining by immunohistochemistry using appropriate WT1-specific antibodies positively correlates, in a statistically significant manner, with the intensities of western blot bands of defined molecular weights and with mRNA levels determined by qRT-PCR. In contrast, the cytoplasmic immunostaining is considered to be non-specific because it did not correlate with any results from other specific examinations. The nuclear immunostaining was hardly observed in primary esophageal, bile duct, pancreatic, or lung cancer although it was firmly observed in mesodermally derived tissues. These results indicate that WT1 expression in those non-mesodermal solid cancers is imperceptible compared to mesodermal tissues. On the other hand, cytoplasmic immunostaining was frequently observed in those solid cancers and WT1 would be estimated to be overexpressed in those solid cancers if researchers consider the cytoplasmic staining as WT1 expression.
Researchers involved in WT1-targeted treatment of cancer presume that WT1 is overexpressed in various malignancies including non-mesodermal solid cancers (17-28). There is little controversy regarding the observation that solid cancers of non-mesodermal origin rarely show nuclear immunostaining but frequently exhibit cytoplasmic immunostaining, while mesodermal tissues provide the nuclear immunostaining (8) (9) (10) (11) (12) (13) (14) (15) (16) (18) (19) (20) (21) (22) (23) (24) 28) . Differences of the conclusions about WT1 expression in non-mesodermal solid cancers stem largely from a discrepancy in interpretations of the cytoplasmic immunostaining. Our conclusion is supported by many pathological studies. Pathologists generally consider the cytoplasmic immunostaining for WT1 as non-specific reaction; they have described that WT1 is hardly expressed in nonmesodermal solid cancers such as colon cancer (0%) (11, 15) , pancreatic cancer (0%) (16) , thyroid cancer (0%) (11), prostate cancer (0%) (11) , lung cancer (0-20%) (8) (9) (10) (11) (12) (13) (14) (15) and breast cancer (0-7%) (11, 13, 15) . The pathologists thus use WT1 to distinguish mesothelioma from lung cancers (8, (10) (11) (12) (13) , or ovarian cancer cells from pancreatic cancer cells in malignant ascites (16) . The present study scientifically supports the pathologists to judge the cytoplasmic immunostaining for WT1 as non-specific. We validated WT1-immunohistochemistry in human cell lines using multiple detection methods but examined WT1 expression in human primary tissues only by immunohistochemistry. It is desirable to present results of western blotting and qRT-PCR in tissue samples because subcellular localization of WT1 protein can differ between cell lines and tissues. however, it should be noted that tissue samples inevitably contain some fraction of stroma and blood; these tissues should not be ignored because they can include cell types that express WT1. Contamination of tumor samples by non-tumor tissues is particularly important in qRT-PCR. Furthermore, because of intra-tumor heterogeneity, samples from different sites of the same cancer do not always exhibit consistent protein expression (42) . On another front, the evaluation of WT1 in the fractionated organelle may be performed when one intends to approach the question regarding to the cytoplasmic WT1. however, the quantitative evaluation of WT1 protein in the cytoplasmic fraction seems to be hard because of the technical difficulty of avoiding the undesired contamination from other fractions. WT1 has multiple isoforms other than the four types of isoforms focused on in the present study; the present study cannot deny the possibility that alternative WT1 transcripts mainly localize in the cytoplasm.
Although the results were obtained from the limited study as described above, they suggest that cytoplasmic staining in immunohistochemistry for WT1 does not reflect actual WT1 expression, WT1 is not overexpressed in non-mesodermal solid cancers, and researchers need to reconsider whether WT1 is an appropriate target of treatment for patients with nonmesodermal solid cancers or not. It is definite that qRT-PCR cannot detect several kinds of WT1 splice variants due to restrictions by the primers. however, western blotting using multiple WT1-specific antibodies is expected to detect more kinds of WT1 splice variants than qRT-PCR and it is not negligible that the cytoplasmic immunostaining did not correlate with western blotting although the nuclear immunostaining did. Because only nuclear immunostaining by WT1-specific monoclonal antibodies correlated with western blotting using the same antibodies, non-coordinate cytoplasmic immunostaining cannot be a reliable indicator of WT1 expression regardless of other putative WT1 splice variants. We do not exclude the possibility that a small amount of WT1 protein may exist in the cytoplasm and the small quantity of WT1 protein can be enough for WT1-targeted immunotherapy to work. Investigating whether WT1-targeted treatment of cancer specifically works for human cells with no nuclear immunostaining but considerable cytoplasmic immunostaining would provide critical information to the problem.
